Health TrialsbyHealthPanel

Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence

ConditionsHCC - Hepatocellular CarcinomaAdjuvant Treatment
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorThe Affiliated Hospital of Xuzhou Medical University

About this trial

Evaluation of the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706) in combination with bevacizumab for postoperative adjuvant treatment of HCC with high-risk recurrence risk

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Voluntarily participate in this study and sign the informed consent form;

Age 18-100 years old, male or female;

Hepatocellular carcinoma confirmed by histopathology, cytology or imaging;

CNLC PHASE I-II;

Disqualifiers

It is known that there are fibrotic plate HCC, sarcomatoid HCC or mixed-type cholangiocarcinoma and HCC;

There is evidence of residual, recurrent or metastatic disease;

History of hepatic encephalopathy;

Previous receipt of allogeneic stem cell or solid organ transplantation, or on the waiting list for liver transplantation;

Trial design

Design model

Single group

Treatments tested in this trial

  • Iparomlimab and Tuvonralimab Injection (QL1706) plus bevacizumab

    Drug

    The patients with high-risk recurrence will be treated with Iparomlimab and Tuvonralimab Injection (QL1706) in combination with bevacizumab for postoperative adjuvant treatment .

Treatment groups

60 Participants
are divided into 1 treatment group
Group A: Iparomlimab and Tuvonralimab Injection (QL1706) plus bevacizumabExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

One-year recurrence-free survival rate

Time frame
From enrollment to the end of treatment at 1 year

Secondary outcomes

1

Relapse-Free Survival at 6 months, RFS6

Time frame
From enrollment to the end of treatment at 6 months
2

Relapse-Free Survival, RFS

Time frame
From enrollment to through study completion, an average of 1 year
3

Time To Relapse, TTR

Time frame
From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first,assessed up to 24 months

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

The Affiliated Hospital of Xuzhou Medical University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: